Treatment and management of MDR-TB in Latvia

Bulletin of the World Health Organization

Volumn 85, Issue 5, 2007, Pages 393-394

  Leimane, Vaira ^a  

^a National TB Registry   (Latvia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

COHORT ANALYSIS; DISEASE CONTROL; DISEASE INCIDENCE; DISEASE TREATMENT; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS;

COHORT ANALYSIS; CONFERENCE PAPER; CONSULTATION; DRUG SENSITIVITY; EUROPEAN UNION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATVIA; LUNG TUBERCULOSIS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; PREVALENCE; SPUTUM SMEAR; SUPERINFECTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS CONTROL;

BALTIC STATES; EURASIA; EUROPE; LATVIA; NORTHERN EUROPE;

EID: 34248142811     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.06.037978     Document Type: Conference Paper

References (11)

1. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: WHO; 2005 (WHO/TB/97.229). Available at: http://www.who.int/tb/surveillanceworkshop/ status_analysis/dr_global_project.htm
2. Zalesky R, Leimans J, Pavlovska I. The epidemiology of tuberculosis in Latvia. Monaldi Archives for Chest Disease 1997; 52(2):142-6.
3. Karklina A, Zaleskis R, Binkin N. Drug-resistant Mycobacterium tuberculosis in Latvia, 1994-1995. Int J Tuberc Lung Dis. 1996; 77(2):63.3-8.
4. WHO guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis. Geneva: WHO; 2000 (WHO/CDS/TB/2000.279).
5. Skenders G. Multidrug-resistant tuberculosis detection, Latvia. Emerg Infect Dis. 2005;11(9):1461-3.
6. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004 MMWR, 2006;55(11):301-5.
7. Nathanson E, Lambrehts-van Weezenbeek C, Rich MI, Gupta R, Bayona J, Blöndal K et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerging Infectious Diseases 2006; 12(9):1389-97.
8. Lasersen KF, Thorpe LE, Leimane V, Weyer K, Mitnick C.D, Riekstina V et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J TB Lung Dis 2005;9(6):640-5.
9. Leimane V, Leimans J. Tuberculosis control in Latvia: integrated DOTS and DOTS Plus program. Euro Surveil 2006;11(3);29-33.
10. Leimane V, Riekstina, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318-26.
11. Morozova I, Riekstina V, Sture G, Wells C, Leimane V. Impact of the growing HIV-I epidemic on multidrug-resistant tuberculosis control in Latvia. Int J Tuberc Lung Dis 2003;7 (9):903-6.